NICE approve Ofatumumab (Kesimpta) for active relapsing MS

Tuesday 20 April 2021

Today the National Institute for Health and Care Excellence (NICE) approved ofatumumab (Kesimpta) as a new treatment option for relapsing MS in adults with active disease.

This follows on from the decision by the Medicines and Healthcare products Regulatory Agency (MHRA), and European Commission (EC).

Ofatumumab is a disease modifying therapy (DMT) which works by targeting a type of immune cell called a B cell.

First self-administered B-cell targeting therapy

Ofatumumab is the first self-administered B-cell targeting therapy to be licensed in the UK.

After initial guidance from a healthcare professional, ofatumumab can be self-injected at home. The licence is based on the results of two Phase III clinical trials, called ASCLEPIOS, which compared ofatumumab to treatment with another existing DMT, teriflunomide (also called Aubagio).

Ofatumumab demonstrated a significant reduction in the number of relapses as compared to teriflunomide.

Who will be able to access ofatumumab?

Ofatumumab has been approved for adults with active relapsing MS. Active disease is defined by MRI scans that identify inflammation or new or enlarging lesions.

The NICE decision applies to England. NHS England has 3 months to make treatment available following a decision, meaning the drug should be available to people living in England by July 2021.

NICE decisions will be checked by the Governments in Wales and Northern Ireland but are usually adopted.

The Scottish Medicine Consortium (SMC) are expected to publish a decision on recommending ofatumumab on the NHS in Scotland this summer (2021).

Making life easier for people who can't attend appointments

Fredi Cavander-Attwood, our Policy Manager says:

“People with MS often tell us about the convenience of being able to have a DMT at home instead of in hospital. Self injecting ofatumumab could be particularly helpful for people who can't take time out of work to attend appointments."

We updated this news story on Tuesday 20 April to reflect the NICE decision.

Ofatumumab (Kesimpta)

Ofatumumab is a disease modifying therapy (DMT) for ‘active’ relapsing MS. Its brand name is Kesimpta and you take it as an injection.

New research for MS Week shows 1/3 people with MS kept it secret

Our findings reveal a third of people with MS (35%) have kept their condition a secret.

A shared goal to stop MS - new funding for research Centres of Excellence

Our two Centres of Excellence in Cambridge and Edinburgh will be working together to find new treatments, faster, for everyone living with MS.

The next research breakthrough is in reach

Your donation will help stop MS.

One-off donation

£30
£50
£100
Other Other amount

£

£30 could process one blood sample, giving researchers crucial information about genes and the immune system.

£50 could pay for an hour on a microscope, so scientists can study cells and tissue in greater detail and improve their understanding of the biology of MS.

£100 could pay for half an hour of MRI use, so researchers can monitor the success of clinical trials and understand MS in more detail.

Every penny you give really does take us a step closer to stopping MS. Your donation will make a difference.

Donate now

Monthly donation

£10
£20
£30
Other Other amount

£

£10 a month could pay for lab equipment like microscope slides to study the building blocks of MS

£20 a month could pay for lab equipment like petri dishes to grow bacteria important for studying genetics

£30 a month could process a blood sample to help us understand what causes MS, so we can stop it in its tracks

Your regular donation means we can keep funding world class MS research with confidence. Together we will stop MS.

Donate now

Researcher wearing a mask looks at MRI scans

NICE approve Ofatumumab (Kesimpta) for active relapsing MS

First self-administered B-cell targeting therapy

Who will be able to access ofatumumab?

Making life easier for people who can't attend appointments